Virax Biolabs Group (NASDAQ:VRAX) Shares Down 3.9% – Here’s What Happened

Virax Biolabs Group Limited (NASDAQ:VRAX) shares were down 3.9% during mid-day trading on Friday . The stock traded as low as $1.20 and last traded at $1.22. Approximately 42,604 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 2,058,643 shares. The stock had previously closed at $1.27.

Virax Biolabs Group Trading Down 3.9 %

The stock’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.99.

Hedge Funds Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd acquired a new stake in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent SEC filing. Hedge funds and other institutional investors own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.